{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T18:36:30Z","timestamp":1770748590346,"version":"3.50.0"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T00:00:00Z","timestamp":1692230400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T00:00:00Z","timestamp":1692230400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Chromosome Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Chromosome instability (CIN) is a cancer hallmark that drives tumour heterogeneity, phenotypic adaptation, drug resistance and poor prognosis. High-grade serous ovarian cancer (HGSOC), one of the most chromosomally unstable tumour types, has a 5-year survival rate of only ~30% \u2014 largely due to late diagnosis and rapid development of drug resistance, e.g., via CIN-driven <jats:italic>ABCB1<\/jats:italic> translocations. However, CIN is also a cell cycle vulnerability that can be exploited to specifically target tumour cells, illustrated by the success of PARP inhibitors to target homologous recombination deficiency (HRD). However, a lack of appropriate models with ongoing CIN has been a barrier to fully exploiting disease-specific CIN mechanisms. This barrier is now being overcome with the development of patient-derived cell cultures and organoids. In this review, we describe our progress building a <jats:italic>Living Biobank<\/jats:italic> of over 120 patient-derived ovarian cancer models (OCMs), predominantly from HGSOC. OCMs are highly purified tumour fractions with extensive proliferative potential that can be analysed at early passage. OCMs have diverse karyotypes, display intra- and inter-patient heterogeneity and mitotic abnormality rates far higher than established cell lines. OCMs encompass a broad-spectrum of HGSOC hallmarks, including a range of p53 alterations and <jats:italic>BRCA1\/2<\/jats:italic> mutations, and display drug resistance mechanisms seen in the clinic, e.g., <jats:italic>ABCB1<\/jats:italic> translocations and <jats:italic>BRCA2<\/jats:italic> reversion. OCMs are amenable to functional analysis, drug-sensitivity profiling, and multi-omics, including single-cell next-generation sequencing, and thus represent a platform for delineating HGSOC-specific CIN mechanisms. In turn, our vision is that this understanding will inform the design of new therapeutic strategies.<\/jats:p>","DOI":"10.1007\/s10577-023-09731-x","type":"journal-article","created":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T16:02:21Z","timestamp":1692288141000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Exploiting a living biobank to delineate mechanisms underlying disease-specific chromosome instability"],"prefix":"10.1007","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8103-3562","authenticated-orcid":false,"given":"Louisa","family":"Nelson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7545-8604","authenticated-orcid":false,"given":"Bethany M.","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7173-232X","authenticated-orcid":false,"given":"Anthony","family":"Tighe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9315-7397","authenticated-orcid":false,"given":"Samantha","family":"Littler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3505-4781","authenticated-orcid":false,"given":"Camilla","family":"Coulson-Gilmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2342-4127","authenticated-orcid":false,"given":"Anya","family":"Golder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3790-177X","authenticated-orcid":false,"given":"Sudha","family":"Desai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0612-0954","authenticated-orcid":false,"given":"Robert D.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7771-8526","authenticated-orcid":false,"given":"Joanne C.","family":"McGrail","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4621-9326","authenticated-orcid":false,"given":"Stephen S.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,8,17]]},"reference":[{"key":"9731_CR1","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.ccr.2007.11.014","volume":"12","author":"AA Ahmed","year":"2007","unstructured":"Ahmed AA, Mills AD, Ibrahim AE, Temple J, Blenkiron C, Vias M, Massie CE, Iyer NG, McGeoch A, Crawford R et al (2007) The extracellular matrix protein TGFBI induces microtubule stabilization and sensitizes ovarian cancers to paclitaxel. Cancer Cell 12:514\u2013527","journal-title":"Cancer Cell"},{"key":"9731_CR2","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s13073-021-00952-5","volume":"13","author":"BM Barnes","year":"2021","unstructured":"Barnes BM, Nelson L, Tighe A, Burghel GJ, Lin IH, Desai S, McGrail JC, Morgan RD, Taylor SS (2021) Distinct transcriptional programs stratify ovarian cancer cell lines into the five major histological subtypes. Genome Med 13:140","journal-title":"Genome Med"},{"key":"9731_CR3","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1290\/0512084.1","volume":"42","author":"CC Bertozzi","year":"2006","unstructured":"Bertozzi CC, Chang CY, Jairaj S, Shan X, Huang J, Weber BL, Chu CS, Carroll RG (2006) Multiple initial culture conditions enhance the establishment of cell lines from primary ovarian cancer specimens. In Vitro Cell Dev Biol Anim 42:58\u201362","journal-title":"In Vitro Cell Dev Biol Anim"},{"key":"9731_CR4","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.cell.2014.12.021","volume":"160","author":"SF Boj","year":"2015","unstructured":"Boj SF, Hwang CI, Baker LA, Chio II, Engle DD, Corbo V, Jager M, Ponz-Sarvise M, Tiriac H, Spector MS et al (2015) Organoid models of human and mouse ductal pancreatic cancer. Cell 160:324\u2013338","journal-title":"Cell"},{"key":"9731_CR5","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/nrc4019","volume":"15","author":"DD Bowtell","year":"2015","unstructured":"Bowtell DD, Bohm S, Ahmed AA, Aspuria PJ, Bast RC Jr, Beral V, Berek JS, Birrer MJ, Blagden S, Bookman MA et al (2015) Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer 15:668\u2013679","journal-title":"Nat Rev Cancer"},{"key":"9731_CR6","doi-asserted-by":"publisher","first-page":"18183","DOI":"10.1038\/s41598-021-97434-w","volume":"11","author":"MN Brodeur","year":"2021","unstructured":"Brodeur MN, Simeone K, Leclerc-Deslauniers K, Fleury H, Carmona E, Provencher DM, Mes-Masson A-M (2021) Carboplatin response in preclinical models for ovarian cancer: comparison of 2D monolayers, spheroids, ex vivo tumors and in vivo models. Sci Rep 11:18183","journal-title":"Sci Rep"},{"key":"9731_CR7","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/nature03443","volume":"434","author":"HE Bryant","year":"2005","unstructured":"Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434:913\u2013917","journal-title":"Nature"},{"key":"9731_CR8","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s41588-023-01320-2","volume":"55","author":"NL Burdett","year":"2023","unstructured":"Burdett NL, Willis MO, Alsop K, Hunt AL, Pandey A, Hamilton PT, Abulez T, Liu X, Hoang T, Craig S et al (2023) Multiomic analysis of homologous recombination-deficient end-stage high-grade serous ovarian cancer. Nat Genet 55:437\u2013450","journal-title":"Nat Genet"},{"key":"9731_CR9","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E et al (2012) The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2:401\u2013404","journal-title":"Cancer Discov"},{"key":"9731_CR10","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1002\/path.4819","volume":"241","author":"YJ Choi","year":"2017","unstructured":"Choi YJ, Rhee JK, Hur SY, Kim MS, Lee SH, Chung YJ, Kim TM, Lee SH (2017) Intraindividual genomic heterogeneity of high-grade serous carcinoma of the ovary and clinical utility of ascitic cancer cells for mutation profiling. J Pathol 241:57\u201366","journal-title":"J Pathol"},{"key":"9731_CR11","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1200\/JCO.2016.70.4627","volume":"35","author":"EL Christie","year":"2017","unstructured":"Christie EL, Fereday S, Doig K, Pattnaik S, Dawson SJ, Bowtell DDL (2017) Reversion of BRCA1\/2 germline mutations detected in circulating tumor DNA from patients with high-grade serous ovarian cancer. J Clin Oncol 35:1274\u20131280","journal-title":"J Clin Oncol"},{"key":"9731_CR12","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1038\/s41467-019-09312-9","volume":"10","author":"EL Christie","year":"2019","unstructured":"Christie EL, Pattnaik S, Beach J, Copeland A, Rashoo N, Fereday S, Hendley J, Alsop K, Brady SL, Lamb G et al (2019) Multiple ABCB1 transcriptional fusions in drug resistant high-grade serous ovarian and breast cancer. Nat Commun 10:1295","journal-title":"Nat Commun"},{"key":"9731_CR13","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1038\/ng.2762","volume":"45","author":"G Ciriello","year":"2013","unstructured":"Ciriello G, Miller ML, Aksoy BA, Senbabaoglu Y, Schultz N, Sander C (2013) Emerging landscape of oncogenic signatures across human cancers. Nat Genet 45:1127\u20131133","journal-title":"Nat Genet"},{"key":"9731_CR14","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1016\/S0140-6736(19)32259-7","volume":"394","author":"AR Clamp","year":"2019","unstructured":"Clamp AR, James EC, McNeish IA, Dean A, Kim JW, O'Donnell DM, Hook J, Coyle C, Blagden S, Brenton JD et al (2019) Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet 394:2084\u20132095","journal-title":"Lancet"},{"key":"9731_CR15","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","volume":"390","author":"RL Coleman","year":"2017","unstructured":"Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp A, Scambia G et al (2017) Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390:1949\u20131961","journal-title":"Lancet"},{"key":"9731_CR16","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1093\/annonc\/mdu116","volume":"25","author":"F Collinson","year":"2014","unstructured":"Collinson F, Qian W, Fossati R, Lissoni A, Williams C, Parmar M, Ledermann J, Colombo N, Swart A (2014) Optimal treatment of early-stage ovarian cancer. Ann Oncol 25:1165\u20131171","journal-title":"Ann Oncol"},{"key":"9731_CR17","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1186\/s13046-021-02124-0","volume":"40","author":"C Coulson-Gilmer","year":"2021","unstructured":"Coulson-Gilmer C, Morgan RD, Nelson L, Barnes BM, Tighe A, Wardenaar R, Spierings DCJ, Schlecht H, Burghel GJ, Foijer F et al (2021) Replication catastrophe is responsible for intrinsic PAR glycohydrolase inhibitor-sensitivity in patient-derived ovarian cancer models. J Exp Clin Cancer Res 40:323","journal-title":"J Exp Clin Cancer Res"},{"key":"9731_CR18","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/j.cub.2011.05.032","volume":"21","author":"JR Daum","year":"2011","unstructured":"Daum JR, Potapova TA, Sivakumar S, Daniel JJ, Flynn JN, Rankin S, Gorbsky GJ (2011) Cohesion fatigue induces chromatid separation in cells delayed at metaphase. Curr Biol 21:1018\u20131024","journal-title":"Curr Biol"},{"key":"9731_CR19","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.1172\/JCI69815","volume":"124","author":"RA Davidowitz","year":"2014","unstructured":"Davidowitz RA, Selfors LM, Iwanicki MP, Elias KM, Karst A, Piao H, Ince TA, Drage MG, Dering J, Konecny GE et al (2014) Mesenchymal gene program-expressing ovarian cancer spheroids exhibit enhanced mesothelial clearance. J Clin Invest 124:2611\u20132625","journal-title":"J Clin Invest"},{"key":"9731_CR20","doi-asserted-by":"publisher","first-page":"107762","DOI":"10.1016\/j.celrep.2020.107762","volume":"31","author":"CJ de Witte","year":"2020","unstructured":"de Witte CJ, Espejo Valle-Inclan J, Hami N, L\u00f5hmussaar K, Kopper O, Vreuls CPH, Jonges GN, van Diest P, Nguyen L, Clevers H et al (2020) Patient-derived ovarian cancer organoids mimic clinical response and exhibit heterogeneous inter- and intrapatient drug responses. Cell Rep 31:107762","journal-title":"Cell Rep"},{"key":"9731_CR21","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1016\/j.jmoldx.2022.09.004","volume":"24","author":"C Denkert","year":"2022","unstructured":"Denkert C, Romey M, Swedlund B, Hattesohl A, Teply-Szymanski J, Kommoss S, Kaiser K, Staebler A, du Bois A, Grass A et al (2022) Homologous recombination deficiency as an ovarian cancer biomarker in a real-world cohort: validation of decentralized genomic profiling. J Mol Diagn 24:1254\u20131263","journal-title":"J Mol Diagn"},{"key":"9731_CR22","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1038\/ncomms3126","volume":"4","author":"S Domcke","year":"2013","unstructured":"Domcke S, Sinha R, Levine DA, Sander C, Schultz N (2013) Evaluating cell lines as tumour models by comparison of genomic profiles. Nat Commun 4:2126","journal-title":"Nat Commun"},{"key":"9731_CR23","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1038\/s41586-022-04789-9","volume":"606","author":"RM Drews","year":"2022","unstructured":"Drews RM, Hernando B, Tarabichi M, Haase K, Lesluyes T, Smith PS, Morrill Gavarr\u00f3 L, Couturier DL, Liu L, Schneider M et al (2022) A pan-cancer compendium of chromosomal instability. Nature 606:976\u2013983","journal-title":"Nature"},{"key":"9731_CR24","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.semcdb.2013.01.003","volume":"24","author":"AW Duncan","year":"2013","unstructured":"Duncan AW (2013) Aneuploidy, polyploidy and ploidy reversal in the liver. Semin Cell Dev Biol 24:347\u2013356","journal-title":"Semin Cell Dev Biol"},{"key":"9731_CR25","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1158\/1078-0432.CCR-08-1564","volume":"15","author":"D Etemadmoghadam","year":"2009","unstructured":"Etemadmoghadam D, deFazio A, Beroukhim R, Mermel C, George J, Getz G, Tothill R, Okamoto A, Raeder MB, Harnett P et al (2009) Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas. Clin Cancer Res 15:1417\u20131427","journal-title":"Clin Cancer Res"},{"key":"9731_CR26","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nature03445","volume":"434","author":"H Farmer","year":"2005","unstructured":"Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C et al (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434:917\u2013921","journal-title":"Nature"},{"key":"9731_CR27","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41416-020-0875-x","volume":"123","author":"CE Ford","year":"2020","unstructured":"Ford CE, Werner B, Hacker NF, Warton K (2020) The untapped potential of ascites in ovarian cancer research and treatment. Br J Cancer 123:9\u201316","journal-title":"Br J Cancer"},{"key":"9731_CR28","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.3390\/cancers12051250","volume":"12","author":"JL Fritz","year":"2020","unstructured":"Fritz JL, Collins O, Saxena P, Buensuceso A, Ramos Valdes Y, Francis KE, Brown KR, Larsen B, Colwill K, Gingras AC et al (2020) A novel role for NUAK1 in promoting ovarian cancer metastasis through regulation of fibronectin production in spheroids. Cancers 12:1250","journal-title":"Cancers"},{"key":"9731_CR29","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.cell.2014.08.016","volume":"159","author":"D Gao","year":"2014","unstructured":"Gao D, Vela I, Sboner A, Iaquinta PJ, Karthaus WR, Gopalan A, Dowling C, Wanjala JN, Undvall EA, Arora VK et al (2014) Organoid cultures derived from patients with advanced prostate cancer. Cell 159:176\u2013187","journal-title":"Cell"},{"key":"9731_CR30","doi-asserted-by":"publisher","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","volume":"6","author":"J Gao","year":"2013","unstructured":"Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E et al (2013) Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6:pl1","journal-title":"Sci Signal"},{"key":"9731_CR31","first-page":"zcac036","volume":"4","author":"A Golder","year":"2022","unstructured":"Golder A, Nelson L, Tighe A, Barnes B, Coulson-Gilmer C, Morgan RD, McGrail JC, Taylor SS (2022) Multiple-low-dose therapy: effective killing of high-grade serous ovarian cancer cells with ATR and CHK1 inhibitors. NAR. Cancer 4:zcac036","journal-title":"Cancer"},{"key":"9731_CR32","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","volume":"381","author":"A Gonzalez-Martin","year":"2019","unstructured":"Gonzalez-Martin A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, McCormick C, Lorusso D, Hoskins P, Freyer G et al (2019) Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 381:2391\u20132402","journal-title":"N Engl J Med"},{"key":"9731_CR33","doi-asserted-by":"publisher","first-page":"761960","DOI":"10.3389\/fonc.2021.761960","volume":"11","author":"W Guo","year":"2021","unstructured":"Guo W, He X, Ni J, Ma L, Cheng X, Wang C, Chen X, Wang Y (2021) High serpin family a member 10 expression confers platinum sensitivity and is associated with survival benefit in high-grade serous ovarian cancer: based on quantitative proteomic analysis. Front Oncol 11:761960","journal-title":"Front Oncol"},{"key":"9731_CR34","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1038\/s43018-021-00222-8","volume":"2","author":"C Gutierrez","year":"2021","unstructured":"Gutierrez C, Al\u2019Khafaji AM, Brenner E, Johnson KE, Gohil SH, Lin Z, Knisbacher BA, Durrett RE, Li S, Parvin S et al (2021) Multifunctional barcoding with ClonMapper enables high-resolution study of clonal dynamics during tumor evolution and treatment. Nat Can 2:758\u2013772","journal-title":"Nat Can"},{"key":"9731_CR35","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.biocel.2009.10.016","volume":"42","author":"J Helleman","year":"2010","unstructured":"Helleman J, Jansen MP, Burger C, van der Burg ME, Berns EM (2010) Integrated genomics of chemotherapy resistant ovarian cancer: a role for extracellular matrix, TGFbeta and regulating microRNAs. Int J Biochem Cell Biol 42:25\u201330","journal-title":"Int J Biochem Cell Biol"},{"key":"9731_CR36","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1158\/2159-8290.CD-18-0474","volume":"8","author":"SJ Hill","year":"2018","unstructured":"Hill SJ, Decker B, Roberts EA, Horowitz NS, Muto MG, Worley MJ Jr, Feltmate CM, Nucci MR, Swisher EM, Nguyen H et al (2018) Prediction of DNA repair inhibitor response in short-term patient-derived ovarian cancer organoids. Cancer Discov 8:1404\u20131421","journal-title":"Cancer Discov"},{"key":"9731_CR37","doi-asserted-by":"publisher","first-page":"e104013","DOI":"10.15252\/embj.2019104013","volume":"39","author":"K Hoffmann","year":"2020","unstructured":"Hoffmann K, Berger H, Kulbe H, Thillainadarasan S, Mollenkopf HJ, Zemojtel T, Taube E, Darb-Esfahani S, Mangler M, Sehouli J et al (2020) Stable expansion of high-grade serous ovarian cancer organoids requires a low-Wnt environment. EMBO J 39:e104013","journal-title":"EMBO J"},{"key":"9731_CR38","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1101\/gr.161026.113","volume":"24","author":"M Hoogstraat","year":"2014","unstructured":"Hoogstraat M, de Pagter MS, Cirkel GA, van Roosmalen MJ, Harkins TT, Duran K, Kreeftmeijer J, Renkens I, Witteveen PO, Lee CC et al (2014) Genomic and transcriptomic plasticity in treatment-naive ovarian cancer. Genome Res 24:200\u2013211","journal-title":"Genome Res"},{"key":"9731_CR39","doi-asserted-by":"publisher","first-page":"546","DOI":"10.4149\/neo_2013_071","volume":"60","author":"H Huang","year":"2013","unstructured":"Huang H, Li YJ, Lan CY, Huang QD, Feng YL, Huang YW, Liu JH (2013) Clinical significance of ascites in epithelial ovarian cancer. Neoplasma 60:546\u2013552","journal-title":"Neoplasma"},{"key":"9731_CR40","doi-asserted-by":"publisher","first-page":"7419","DOI":"10.1038\/ncomms8419","volume":"6","author":"TA Ince","year":"2015","unstructured":"Ince TA, Sousa AD, Jones MA, Harrell JC, Agoston ES, Krohn M, Selfors LM, Liu W, Chen K, Yong M et al (2015) Characterization of twenty-five ovarian tumour cell lines that phenocopy primary tumours. Nat Commun 6:7419","journal-title":"Nat Commun"},{"key":"9731_CR41","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1016\/j.devcel.2021.07.006","volume":"56","author":"MR Ippolito","year":"2021","unstructured":"Ippolito MR, Martis V, Martin S, Tijhuis AE, Hong C, Wardenaar R, Dumont M, Zerbib J, Spierings DCJ, Fachinetti D et al (2021) Gene copy-number changes and chromosomal instability induced by aneuploidy confer resistance to chemotherapy. Dev Cell 56:2440\u20132454.e2446","journal-title":"Dev Cell"},{"key":"9731_CR42","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1007\/s13577-022-00827-w","volume":"36","author":"Y Ito","year":"2023","unstructured":"Ito Y, Kondo J, Masuda M, Matsuzaki S, Onuma K, Kanda M, Watanabe Y, Sakaguchi H, Yoshino K, Ueda Y et al (2023) Ex vivo chemosensitivity assay using primary ovarian cancer organoids for predicting clinical response and screening effective drugs. Hum Cell 36:752\u2013761","journal-title":"Hum Cell"},{"key":"9731_CR43","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1016\/S0140-6736(13)62146-7","volume":"384","author":"GC Jayson","year":"2014","unstructured":"Jayson GC, Kohn EC, Kitchener HC, Ledermann JA (2014) Ovarian cancer. Lancet 384:1376\u20131388","journal-title":"Lancet"},{"key":"9731_CR44","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/nrc3432","volume":"13","author":"E Kipps","year":"2013","unstructured":"Kipps E, Tan DS, Kaye SB (2013) Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. Nat Rev Cancer 13:273\u2013282","journal-title":"Nat Rev Cancer"},{"issue":"200-211","key":"9731_CR45","first-page":"e213","volume":"175","author":"KA Knouse","year":"2018","unstructured":"Knouse KA, Lopez KE, Bachofner M, Amon A (2018) Chromosome segregation fidelity in epithelia requires tissue architecture. Cell 175(200-211):e213","journal-title":"Cell"},{"key":"9731_CR46","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1038\/s41591-019-0422-6","volume":"25","author":"O Kopper","year":"2019","unstructured":"Kopper O, de Witte CJ, Lohmussaar K, Valle-Inclan JE, Hami N, Kester L, Balgobind AV, Korving J, Proost N, Begthel H et al (2019) An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity. Nat Med 25:838\u2013849","journal-title":"Nat Med"},{"key":"9731_CR47","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.tips.2020.01.001","volume":"41","author":"N Kozlova","year":"2020","unstructured":"Kozlova N, Grossman JE, Iwanicki MP, Muranen T (2020) The interplay of the extracellular matrix and stromal cells as a drug target in stroma-rich cancers. Trends Pharmacol Sci 41:183\u2013198","journal-title":"Trends Pharmacol Sci"},{"key":"9731_CR48","doi-asserted-by":"publisher","first-page":"e46858","DOI":"10.1371\/journal.pone.0046858","volume":"7","author":"A Latifi","year":"2012","unstructured":"Latifi A, Luwor RB, Bilandzic M, Nazaretian S, Stenvers K, Pyman J, Zhu H, Thompson EW, Quinn MA, Findlay JK, Ahmed N (2012) Isolation and characterization of tumor cells from the ascites of ovarian cancer patients: molecular phenotype of chemoresistant ovarian tumors. PLoS One 7:e46858","journal-title":"PLoS One"},{"key":"9731_CR49","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/386623a0","volume":"386","author":"C Lengauer","year":"1997","unstructured":"Lengauer C, Kinzler KW, Vogelstein B (1997) Genetic instability in colorectal cancers. Nature 386:623\u2013627","journal-title":"Nature"},{"key":"9731_CR50","doi-asserted-by":"publisher","first-page":"3619","DOI":"10.1038\/onc.2013.321","volume":"33","author":"E Lengyel","year":"2014","unstructured":"Lengyel E, Burdette JE, Kenny HA, Matei D, Pilrose J, Haluska P, Nephew KP, Hales DB, Stack MS (2014) Epithelial ovarian cancer experimental models. Oncogene 33:3619\u20133633","journal-title":"Oncogene"},{"key":"9731_CR51","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1158\/1078-0432.CCR-16-1237","volume":"23","author":"JF Liu","year":"2017","unstructured":"Liu JF, Palakurthi S, Zeng Q, Zhou S, Ivanova E, Huang W, Zervantonakis IK, Selfors LM, Shen Y, Pritchard CC et al (2017) Establishment of patient-derived tumor xenograft models of epithelial ovarian cancer for preclinical evaluation of novel therapeutics. Clin Cancer Res 23:1263\u20131273","journal-title":"Clin Cancer Res"},{"key":"9731_CR52","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1016\/j.devcel.2021.07.009","volume":"56","author":"DA Lukow","year":"2021","unstructured":"Lukow DA, Sausville EL, Suri P, Chunduri NK, Wieland A, Leu J, Smith JC, Girish V, Kumar AA, Kendall J et al (2021) Chromosomal instability accelerates the evolution of resistance to anti-cancer therapies. Dev Cell 56:2427\u20132439.e2424","journal-title":"Dev Cell"},{"key":"9731_CR53","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1038\/s41588-018-0179-8","volume":"50","author":"G Macintyre","year":"2018","unstructured":"Macintyre G, Goranova TE, De Silva D, Ennis D, Piskorz AM, Eldridge M, Sie D, Lewsley LA, Hanif A, Wilson C et al (2018) Copy number signatures and mutational processes in ovarian carcinoma. Nat Genet 50:1262\u20131270","journal-title":"Nat Genet"},{"key":"9731_CR54","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.stemcr.2020.03.004","volume":"14","author":"N Maenhoudt","year":"2020","unstructured":"Maenhoudt N, Defraye C, Boretto M, Jan Z, Heremans R, Boeckx B, Hermans F, Arijs I, Cox B, Van Nieuwenhuysen E et al (2020) Developing organoids from ovarian cancer as experimental and preclinical models. Stem Cell Reports 14:717\u2013729","journal-title":"Stem Cell Reports"},{"key":"9731_CR55","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ygyno.2019.05.005","volume":"154","author":"Y Maru","year":"2019","unstructured":"Maru Y, Tanaka N, Itami M, Hippo Y (2019) Efficient use of patient-derived organoids as a preclinical model for gynecologic tumors. Gynecol Oncol 154:189\u2013198","journal-title":"Gynecol Oncol"},{"key":"9731_CR56","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41580-021-00404-3","volume":"23","author":"HK Matthews","year":"2022","unstructured":"Matthews HK, Bertoli C, de Bruin RAM (2022) Cell cycle control in cancer. Nat Rev Mol Cell Biol 23:74\u201388","journal-title":"Nat Rev Mol Cell Biol"},{"key":"9731_CR57","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1093\/annonc\/mdx010","volume":"28","author":"J McGee","year":"2017","unstructured":"McGee J, Bookman M, Harter P, Marth C, McNeish I, Moore KN, Poveda A, Hilpert F, Hasegawa K, Bacon M et al (2017) Fifth Ovarian Cancer Consensus Conference: individualized therapy and patient factors. Ann Oncol 28:702\u2013710","journal-title":"Ann Oncol"},{"key":"9731_CR58","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1038\/ng.3573","volume":"48","author":"A McPherson","year":"2016","unstructured":"McPherson A, Roth A, Laks E, Masud T, Bashashati A, Zhang AW, Ha G, Biele J, Yap D, Wan A et al (2016) Divergent modes of clonal spread and intraperitoneal mixing in high-grade serous ovarian cancer. Nat Genet 48:758\u2013767","journal-title":"Nat Genet"},{"key":"9731_CR59","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","volume":"375","author":"MR Mirza","year":"2016","unstructured":"Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, Fabbro M, Ledermann JA, Lorusso D, Vergote I et al (2016) Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med 375:2154\u20132164","journal-title":"N Engl J Med"},{"key":"9731_CR60","doi-asserted-by":"publisher","first-page":"3952","DOI":"10.1200\/JCO.22.01003","volume":"40","author":"BJ Monk","year":"2022","unstructured":"Monk BJ, Parkinson C, Lim MC, O'Malley DM, Oaknin A, Wilson MK, Coleman RL, Lorusso D, Bessette P, Ghamande S et al (2022) A randomized, phase III trial to evaluate rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA-MONO\/GOG-3020\/ENGOT-ov45). J Clin Oncol 40:3952\u20133964","journal-title":"J Clin Oncol"},{"key":"9731_CR61","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","volume":"379","author":"K Moore","year":"2018","unstructured":"Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS et al (2018) Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 379:2495\u20132505","journal-title":"N Engl J Med"},{"key":"9731_CR62","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1136\/ijgc-2022-004211","volume":"33","author":"RD Morgan","year":"2023","unstructured":"Morgan RD, Clamp AR, Barnes BM, Timms K, Schlecht H, Yarram-Smith L, Wallis Y, Valganon-Petrizan M, MacMahon S, White R et al (2023a) Homologous recombination deficiency in newly diagnosed FIGO stage III\/IV high-grade epithelial ovarian cancer: a multi-national observational study. Int J Gynecol Cancer 33:1253\u20131259","journal-title":"Int J Gynecol Cancer"},{"key":"9731_CR63","doi-asserted-by":"publisher","first-page":"2602","DOI":"10.1158\/1078-0432.CCR-22-3282","volume":"29","author":"RD Morgan","year":"2023","unstructured":"Morgan RD, Clamp AR, White DJ, Price M, Burghel GJ, Ryder WDJ, Mahmood RD, Murphy AD, Hasan J, Mitchell CL et al (2023b) Multi-maintenance Olaparib therapy in relapsed, germline BRCA1\/2-mutant high-grade serous ovarian cancer (MOLTO): a phase II trial. Clin Cancer Res 29:2602\u20132611","journal-title":"Clin Cancer Res"},{"key":"9731_CR64","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S1470-2045(20)30591-X","volume":"22","author":"RD Morgan","year":"2021","unstructured":"Morgan RD, McNeish IA, Cook AD, James EC, Lord R, Dark G, Glasspool RM, Krell J, Parkinson C, Poole CJ et al (2021) Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. Lancet Oncol 22:277\u2013288","journal-title":"Lancet Oncol"},{"key":"9731_CR65","doi-asserted-by":"publisher","first-page":"5799","DOI":"10.1038\/s41467-020-19584-1","volume":"11","author":"S Naffar-Abu Amara","year":"2020","unstructured":"Naffar-Abu Amara S, Kuiken HJ, Selfors LM, Butler T, Leung ML, Leung CT, Kuhn EP, Kolarova T, Hage C, Ganesh K et al (2020) Transient commensal clonal interactions can drive tumor metastasis. Nat Commun 11:5799","journal-title":"Nat Commun"},{"key":"9731_CR66","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/s41467-020-14551-2","volume":"11","author":"L Nelson","year":"2020","unstructured":"Nelson L, Tighe A, Golder A, Littler S, Bakker B, Moralli D, Murtuza Baker S, Donaldson IJ, Spierings DCJ, Wardenaar R et al (2020) A living biobank of ovarian cancer ex vivo models reveals profound mitotic heterogeneity. Nat Commun 11:822","journal-title":"Nat Commun"},{"key":"9731_CR67","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cels.2019.06.005","volume":"9","author":"M Niepel","year":"2019","unstructured":"Niepel M, Hafner M, Mills CE, Subramanian K, Williams EH, Chung M, Gaudio B, Barrette AM, Stern AD, Hu B et al (2019) A multi-center study on the reproducibility of drug-response assays in mammalian cell lines. Cell Syst 9:35\u201348.e35","journal-title":"Cell Syst"},{"key":"9731_CR68","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/nature14410","volume":"521","author":"AM Patch","year":"2015","unstructured":"Patch AM, Christie EL, Etemadmoghadam D, Garsed DW, George J, Fereday S, Nones K, Cowin P, Alsop K, Bailey PJ et al (2015) Whole-genome characterization of chemoresistant ovarian cancer. Nature 521:489\u2013494","journal-title":"Nature"},{"key":"9731_CR69","doi-asserted-by":"publisher","first-page":"e1006707","DOI":"10.1371\/journal.pgen.1006707","volume":"13","author":"S Penner-Goeke","year":"2017","unstructured":"Penner-Goeke S, Lichtensztejn Z, Neufeld M, Ali JL, Altman AD, Nachtigal MW, McManus KJ (2017) The temporal dynamics of chromosome instability in ovarian cancer cell lines and primary patient samples. PLoS Genet 13:e1006707","journal-title":"PLoS Genet"},{"key":"9731_CR70","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s42003-019-0305-x","volume":"2","author":"N Phan","year":"2019","unstructured":"Phan N, Hong JJ, Tofig B, Mapua M, Elashoff D, Moatamed NA, Huang J, Memarzadeh S, Damoiseaux R, Soragni A (2019) A simple high-throughput approach identifies actionable drug sensitivities in patient-derived tumor organoids. Commun Biol 2:78","journal-title":"Commun Biol"},{"issue":"519-533","key":"9731_CR71","first-page":"e518","volume":"35","author":"N Pillay","year":"2019","unstructured":"Pillay N, Tighe A, Nelson L, Littler S, Coulson-Gilmer C, Bah N, Golder A, Bakker B, Spierings DCJ, James DI et al (2019) DNA replication vulnerabilities render ovarian cancer cells sensitive to poly(ADP-Ribose) glycohydrolase inhibitors. Cancer Cell 35(519-533):e518","journal-title":"Cancer Cell"},{"key":"9731_CR72","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","volume":"18","author":"E Pujade-Lauraine","year":"2017","unstructured":"Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, Korach J, Huzarski T, Poveda A, Pignata S et al (2017) Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 18:1274\u20131284","journal-title":"Lancet Oncol"},{"issue":"373-386","key":"9731_CR73","first-page":"e310","volume":"172","author":"N Sachs","year":"2018","unstructured":"Sachs N, de Ligt J, Kopper O, Gogola E, Bounova G, Weeber F, Balgobind AV, Wind K, Gracanin A, Begthel H et al (2018) A living biobank of breast cancer organoids captures disease heterogeneity. Cell 172(373-386):e310","journal-title":"Cell"},{"key":"9731_CR74","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1053\/j.gastro.2011.07.050","volume":"141","author":"T Sato","year":"2011","unstructured":"Sato T, Stange DE, Ferrante M, Vries RG, Van Es JH, Van den Brink S, Van Houdt WJ, Pronk A, Van Gorp J, Siersema PD, Clevers H (2011) Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium. Gastroenterology 141:1762\u20131772","journal-title":"Gastroenterology"},{"key":"9731_CR75","doi-asserted-by":"publisher","first-page":"e1001789","DOI":"10.1371\/journal.pmed.1001789","volume":"12","author":"RF Schwarz","year":"2015","unstructured":"Schwarz RF, Ng CK, Cooke SL, Newman S, Temple J, Piskorz AM, Gale D, Sayal K, Murtaza M, Baldwin PJ et al (2015) Spatial and temporal heterogeneity in high-grade serous ovarian cancer: a phylogenetic analysis. PLoS Med 12:e1001789","journal-title":"PLoS Med"},{"key":"9731_CR76","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1038\/s41588-018-0212-y","volume":"50","author":"SP Shah","year":"2018","unstructured":"Shah SP (2018) Copy number signatures in ovarian cancer. Nat Genet 50:1208\u20131209","journal-title":"Nat Genet"},{"key":"9731_CR77","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1038\/nprot.2006.328","volume":"1","author":"TG Shepherd","year":"2006","unstructured":"Shepherd TG, Th\u00e9riault BL, Campbell EJ, Nachtigal MW (2006) Primary culture of ovarian surface epithelial cells and ascites-derived ovarian cancer cells from patients. Nat Protoc 1:2643\u20132649","journal-title":"Nat Protoc"},{"key":"9731_CR78","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1038\/s41586-022-04738-6","volume":"606","author":"CD Steele","year":"2022","unstructured":"Steele CD, Abbasi A, Islam SMA, Bowes AL, Khandekar A, Haase K, Hames-Fathi S, Ajayi D, Verfaillie A, Dhami P et al (2022) Signatures of copy number alterations in human cancer. Nature 606:984\u2013991","journal-title":"Nature"},{"key":"9731_CR79","doi-asserted-by":"publisher","first-page":"e22969","DOI":"10.1371\/journal.pone.0022969","volume":"6","author":"D Stevens","year":"2011","unstructured":"Stevens D, Gassmann R, Oegema K, Desai A (2011) Uncoordinated loss of chromatid cohesion is a common outcome of extended metaphase arrest. PLoS One 6:e22969","journal-title":"PLoS One"},{"key":"9731_CR80","doi-asserted-by":"publisher","first-page":"e50519","DOI":"10.1371\/journal.pone.0050519","volume":"7","author":"T Sueblinvong","year":"2012","unstructured":"Sueblinvong T, Ghebre R, Iizuka Y, Pambuccian SE, Isaksson Vogel R, Skubitz AP, Bazzaro M (2012) Establishment, characterization and downstream application of primary ovarian cancer cells derived from solid tumors. PLoS One 7:e50519","journal-title":"PLoS One"},{"key":"9731_CR81","doi-asserted-by":"publisher","first-page":"4946","DOI":"10.1158\/0008-5472.CAN-19-0852","volume":"80","author":"N Tamura","year":"2020","unstructured":"Tamura N, Shaikh N, Muliaditan D, Soliman TN, McGuinness JR, Maniati E, Moralli D, Durin MA, Green CM, Balkwill FR et al (2020) Specific mechanisms of chromosomal instability indicate therapeutic sensitivities in high-grade serous ovarian carcinoma. Cancer Res 80:4946\u20134959","journal-title":"Cancer Res"},{"key":"9731_CR82","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nature10166","volume":"474","author":"TCGA","year":"2011","unstructured":"TCGA (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474:609\u2013615","journal-title":"Nature"},{"key":"9731_CR83","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/978-1-62703-547-7_24","volume":"1049","author":"BL Th\u00e9riault","year":"2013","unstructured":"Th\u00e9riault BL, Portelance L, Mes-Masson AM, Nachtigal MW (2013) Establishment of primary cultures from ovarian tumor tissue and ascites fluid. Methods Mol Biol 1049:323\u2013336","journal-title":"Methods Mol Biol"},{"key":"9731_CR84","doi-asserted-by":"publisher","first-page":"50489","DOI":"10.18632\/oncotarget.9929","volume":"8","author":"KL Thu","year":"2017","unstructured":"Thu KL, Papari-Zareei M, Stastny V, Song K, Peyton M, Martinez VD, Zhang YA, Castro IB, Varella-Garcia M, Liang H et al (2017) A comprehensively characterized cell line panel highly representative of clinical ovarian high-grade serous carcinomas. Oncotarget 8:50489\u201350499","journal-title":"Oncotarget"},{"key":"9731_CR85","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13048-023-01145-x","volume":"16","author":"E Tomas","year":"2023","unstructured":"Tomas E, Shepherd TG (2023) Insights into high-grade serous carcinoma pathobiology using three-dimensional culture model systems. J Ovarian Res 16:70","journal-title":"Journal of Ovarian Research"},{"key":"9731_CR86","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1093\/jnci\/95.2.113","volume":"95","author":"JB Trimbos","year":"2003","unstructured":"Trimbos JB, Vergote I, Bolis G, Vermorken JB, Mangioni C, Madronal C, Franchi M, Tateo S, Zanetta G, Scarfone G et al (2003) Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European organisation for research and treatment of cancer\u2013adjuvant chemotherapy in ovarian neoplasm trial. J Natl Cancer Inst 95:113\u2013125","journal-title":"J Natl Cancer Inst"},{"key":"9731_CR87","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.devcel.2020.01.034","volume":"52","author":"A Vasudevan","year":"2020","unstructured":"Vasudevan A, Baruah PS, Smith JC, Wang Z, Sayles NM, Andrews P, Kendall J, Leu J, Chunduri NK, Levy D et al (2020) Single-chromosomal gains can function as metastasis suppressors and promoters in colon cancer. Dev Cell 52:413\u2013428.e416","journal-title":"Dev Cell"},{"key":"9731_CR88","doi-asserted-by":"publisher","first-page":"e83867","DOI":"10.7554\/eLife.83867","volume":"12","author":"M Vias","year":"2023","unstructured":"Vias M, Morrill Gavarr\u00f3 L, Sauer CM, Sanders DA, Piskorz AM, Couturier D-L, Ballereau SP, Hernando B, Schneider MP, Hall J et al (2023) High-grade serous ovarian carcinoma organoids as models of chromosomal instability. Elife 12:e83867","journal-title":"Elife"},{"key":"9731_CR89","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1038\/ng.3849","volume":"49","author":"YK Wang","year":"2017","unstructured":"Wang YK, Bashashati A, Anglesio MS, Cochrane DR, Grewal DS, Ha G, McPherson A, Horlings HM, Senz J, Prentice LM et al (2017) Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes. Nat Genet 49:856\u2013865","journal-title":"Nat Genet"},{"key":"9731_CR90","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1093\/carcin\/bgy068","volume":"39","author":"D Wangsa","year":"2018","unstructured":"Wangsa D, Braun R, Schiefer M, Gertz EM, Bronder D, Quintanilla I, Padilla-Nash HM, Torres I, Hunn C, Warner L et al (2018) The evolution of single cell-derived colorectal cancer cell lines is dominated by the continued selection of tumor-specific genomic imbalances, despite random chromosomal instability. Carcinogenesis 39:993\u20131005","journal-title":"Carcinogenesis"},{"key":"9731_CR91","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1186\/s12885-020-07571-0","volume":"20","author":"MS Williams","year":"2020","unstructured":"Williams MS, Basma NJ, Amaral FMR, Williams G, Weightman JP, Breitwieser W, Nelson L, Taylor SS, Wiseman DH, Somervaille TCP (2020) Targeted nanopore sequencing for the identification of ABCB1 promoter translocations in cancer. BMC Cancer 20:1075","journal-title":"BMC Cancer"}],"container-title":["Chromosome Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10577-023-09731-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10577-023-09731-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10577-023-09731-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T04:13:55Z","timestamp":1695615235000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10577-023-09731-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,17]]},"references-count":91,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["9731"],"URL":"https:\/\/doi.org\/10.1007\/s10577-023-09731-x","relation":{},"ISSN":["1573-6849"],"issn-type":[{"value":"1573-6849","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,17]]},"assertion":[{"value":"25 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"OCMs were established and characteristics published previously (Nelson et al. ; Barnes et al. ; Coulson-Gilmer et al. ; Golder et al. ). The research samples were obtained with informed patient consent from the Manchester Cancer Research Centre (MCRC) Biobank. The MCRC Biobank is licensed by the Human Tissue Authority (license number: 30004) and is ethically approved as a research tissue bank by the South Manchester Research Ethics Committee (Ref: 22\/NW\/0237). The role of the MCRC Biobank is to distribute samples and does not endorse studies performed or the interpretation of results. For more information, see .","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Research samples were obtained with informed patient consent from the MCRC Biobank (see above).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21"}}